Thursday, July 10, 2014
The precise cause of neurodegeneration in Parkinson's
disease remains unknown, and as a result no one has been able to develop a
truly disease-modifying therapy. Now, independent teams in Europe and the U.S.
have found that the dopamine transporter VMAT2
has a potentially causative role in the disease1,2-figuring out how
to enhance its activity is the next challenge.
team measured dopamine levels and VMAT2 activity in brain lysates from six
patients with idiopathic PD and four healthy controls. The lysates were
harvested shortly after death, before dopamine-laden intracellular vesicles
Going to the
Pifl's findings imply that increasing VMAT2 activity could have a therapeutic
effect, Miller's mouse findings show this is indeed the case.
L. SciBX 7(26); doi:10.1038/scibx.2014.755
Published online July 10, 2014
1. Pifl, C. et al. J. Neurosci.;
published online June 11, 2014; doi:10.1523/JNEUROSCI.5456-13.2014
Contact: Christian Pifl, Medical University of Vienna,
2. Lohr, K.M. et al. Proc. Natl. Acad. Sci. USA;
June 16, 2014; doi:10.1073/pnas.1402134111
Contact: Gary W. Miller, Emory University, Atlanta, Ga.
3. Edwards, R.H. Ann.
Neurol. 34, 638-645 (1993)
4. Mosharov, E.V. et
al. Neuron 62, 218-229 (2009)
5. Hu, G. et al. ACS
Chem. Biol. 8, 1947-1954 (2013)
AND INSTITUTIONS MENTIONED
Columbia University, New York, N.Y.
Emory University Rollins School of Public Health, Atlanta, Ga.
Medical University of Vienna, Vienna, Austria
University of California, San Francisco, Calif.